Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice.

IF 2.7 3区 医学 Q3 ONCOLOGY
Tobias Berg, Maj-Britt Jensen, Maria Rossing, Christian T Axelsen, Iben Kümler, Lise Søndergaard, Marianne Vogsen, Ann S Knoop, Bent Ejlertsen
{"title":"Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice.","authors":"Tobias Berg, Maj-Britt Jensen, Maria Rossing, Christian T Axelsen, Iben Kümler, Lise Søndergaard, Marianne Vogsen, Ann S Knoop, Bent Ejlertsen","doi":"10.2340/1651-226X.2023.37270","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary metastatic breast cancer (pMBC) accounts for 5-10% of annual breast cancers with a median survival of 3-4 years, varying among subtypes. In Denmark, the incidence of breast cancer increased until 2010, followed by a stabilisation. Several factors influencing pMBC incidence and survival, including screening prevalence, staging methods, and classification standards, remain pivotal but inadequately documented.</p><p><strong>Material and method: </strong>This retrospective observational study involving pMBC patients diagnosed between 2000 and 2020 encompassed all Danish oncology departments. Data from the Danish Breast Cancer Group database and the National Patient Register included diagnosis specifics, demographics, treatment, and follow-up.</p><p><strong>Results: </strong>Between 2000 and 2020, 3,272 patients were diagnosed with pMBC, a rise from 355 patients in 2000-2004 to 1,323 patients in 2015-2020. The increase was particularly observed in patients aged 70 years or older. Changes in tumour subtypes were observed, notably with a rise in human epidermal growth factor receptor 2 (HER2)-positive cases but a steady distribution of estrogen receptor (ER) status. Diagnostic practices changed over the two decades, with 6% evaluated with PET/CT (positron emission tomography-computed tomography) or CT (computed tomography) with a bone evaluation in 2000-2004 and 65% in 2015-2020. Overall survival (OS) improved from 23 months in 2000-2004 to 33 months in 2015-2020. In patients with ER-positive and HER2-positive disease, the multivariable model showed improved survival by year of diagnosis, and further, patients with ER-negative/HER2-negative disease fared worse the first 2 years after diagnosis.</p><p><strong>Interpretation: </strong>Our study delineates changes in the treatment and survival of pMBC over two decades. Stage migration, screening introduction, and changes in registration practice, however, prevent a valid assessment of a possible causal relationship.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"63 ","pages":"277-287"},"PeriodicalIF":2.7000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332488/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Oncologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/1651-226X.2023.37270","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Primary metastatic breast cancer (pMBC) accounts for 5-10% of annual breast cancers with a median survival of 3-4 years, varying among subtypes. In Denmark, the incidence of breast cancer increased until 2010, followed by a stabilisation. Several factors influencing pMBC incidence and survival, including screening prevalence, staging methods, and classification standards, remain pivotal but inadequately documented.

Material and method: This retrospective observational study involving pMBC patients diagnosed between 2000 and 2020 encompassed all Danish oncology departments. Data from the Danish Breast Cancer Group database and the National Patient Register included diagnosis specifics, demographics, treatment, and follow-up.

Results: Between 2000 and 2020, 3,272 patients were diagnosed with pMBC, a rise from 355 patients in 2000-2004 to 1,323 patients in 2015-2020. The increase was particularly observed in patients aged 70 years or older. Changes in tumour subtypes were observed, notably with a rise in human epidermal growth factor receptor 2 (HER2)-positive cases but a steady distribution of estrogen receptor (ER) status. Diagnostic practices changed over the two decades, with 6% evaluated with PET/CT (positron emission tomography-computed tomography) or CT (computed tomography) with a bone evaluation in 2000-2004 and 65% in 2015-2020. Overall survival (OS) improved from 23 months in 2000-2004 to 33 months in 2015-2020. In patients with ER-positive and HER2-positive disease, the multivariable model showed improved survival by year of diagnosis, and further, patients with ER-negative/HER2-negative disease fared worse the first 2 years after diagnosis.

Interpretation: Our study delineates changes in the treatment and survival of pMBC over two decades. Stage migration, screening introduction, and changes in registration practice, however, prevent a valid assessment of a possible causal relationship.

丹麦原发性转移性乳腺癌的发病率和生存率;乳腺癌筛查、分类和分期做法的影响。
背景:原发性转移性乳腺癌(pMBC)占每年乳腺癌发病率的 5-10%,中位生存期为 3-4 年,因亚型而异。在丹麦,乳腺癌的发病率在 2010 年之前一直呈上升趋势,随后趋于稳定。影响pMBC发病率和存活率的几个因素,包括筛查普及率、分期方法和分类标准,仍然至关重要,但文献记载不足:这项回顾性观察研究涉及 2000 年至 2020 年期间确诊的 pMBC 患者,涵盖丹麦所有肿瘤科。来自丹麦乳腺癌小组数据库和全国患者登记册的数据包括诊断细节、人口统计学、治疗和随访:2000年至2020年期间,共有3272名患者被确诊为pMBC,从2000年至2004年的355名患者增加到2015年至2020年的1323名患者。这一增长在 70 岁或以上的患者中尤为明显。肿瘤亚型也发生了变化,特别是人表皮生长因子受体2(HER2)阳性病例有所增加,但雌激素受体(ER)状态的分布保持稳定。诊断方法在二十年间发生了变化,2000-2004年,6%的病例通过PET/CT(正电子发射断层扫描-计算机断层扫描)或CT(计算机断层扫描)进行了骨评估,2015-2020年,65%的病例通过PET/CT(正电子发射断层扫描-计算机断层扫描)或CT(计算机断层扫描)进行了骨评估。总生存期(OS)从2000-2004年的23个月提高到2015-2020年的33个月。在ER阳性和HER2阳性患者中,多变量模型显示,确诊当年的生存率有所提高,此外,ER阴性/HER2阴性患者在确诊后头两年的情况较差:我们的研究描述了二十年来 pMBC 治疗和生存率的变化。然而,分期迁移、筛查的引入以及注册实践的变化阻碍了对可能的因果关系进行有效评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Oncologica
Acta Oncologica 医学-肿瘤学
CiteScore
4.30
自引率
3.20%
发文量
301
审稿时长
3 months
期刊介绍: Acta Oncologica is a journal for the clinical oncologist and accepts articles within all fields of clinical cancer research. Articles on tumour pathology, experimental oncology, radiobiology, cancer epidemiology and medical radio physics are also welcome, especially if they have a clinical aim or interest. Scientific articles on cancer nursing and psychological or social aspects of cancer are also welcomed. Extensive material may be published as Supplements, for which special conditions apply.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信